MedImmune are a global leader in Biologics research for Therapeutic use. Oncology is a key therapeutic area for a number of our research teams and as part of the CAFFEIN European collaboration we are proud to offer a Post-Doctoral position funded by the European Commission (EC).
The CAFFEIN consortium (www.caffein.ku.dk) is an FP7 EC funded Marie Curie Initial Training Network (ITN) with the objective to train young scientists in the important role of cancer associated fibroblast (CAF) for tumour cell expansion and invasion. In a trans-European network MedImmune Cambridge and ten academic partners aim to identify functional CAF subpopulations and CAF effector mechanisms, and to develop therapeutic antibodies targeting CAFs as a novel approach in cancer therapy.
CAFFEIN consists of leading European research groups and companies with complementary knowledge in this area and a critical mass of expertise for providing an excellent training in CAF function and translational cancer research. We currently seek a post-doctoral fellow with a high motivation, high interest in cancer research and the willingness to work in a team of academic and industrial partners in different European countries.
As a Marie Curie funded post all applicants must fulfil specific criteria to be eligible for consideration (This information can be identified at the end of the advert).
Should you fulfil these criteria and possess the experience outlined below this 24 month post present a significant opportunity to develop your academic and technical skills further and gain exposure to a dynamic industrial research setting.
- Understand the role of cancer associated fibroblasts (CAF) and identify therapeutic potential of targeting these cells during cancer development and progression.
- Develop, design and run in vitro and in vivo models.
- Understand the crosstalk between tumour cells/Immune cells and cancer associated fibroblasts, and how this affects cancer cell survival and dissemination
- Isolate primary cancer associate fibroblasts from primary tumours and/or relevant pre-clinical cancer models.
- Understand how approved therapies affects the crosstalk between tumour cells and CAFs
- Link with the technology team to establish phenotypic selection strategy for the discovery of novel drug targets and/or prognostic and responsive biomarkers
- Pursue one or two targets and further assess the therapeutic potential using knock in and knock out strategies
- Communicate results, conclusions and recommendations to colleagues, line manager and multi-disciplinary teams and developing a publishing strategy
- Acquire and maintain relevant technical and intellectual expertise in stroma biology (angiogenesis immune cells and cancer associated fibroblasts), 3D models and in vivo models.
- Be a highly organized, self-motivated individual with a strong practical background.
- Engage regularly with the consortium collaborators and attend consortium training, knowledge generation and dissemination.